Anondita Medi. announces a new order win

The 8 crore-unit CMSS tender cannot be assigned a definitive revenue contribution because the L1 disclosure does not report the contract value or quoted price per unit ^[1]. Against FY24 total operating income of Rs 46.43 Crores ^[2], the calculation is:

• Estimated tender revenue: Rs 8 Crores × quoted price per unit in rupees
• Contribution to FY24 revenue: `(8 × quoted price) / 46.43`
• Equivalently, every Rs 1 per unit of quoted price would represent Rs 8 Crores of revenue, or 17.23% of FY24 revenue.

As a reference point only, a separate CMSS order disclosed at Rs 2.9241 Crores ^[3] implies approximately Rs 0.37 per unit if applied to an 8 crore-unit volume. At that price, the tender would represent approximately Rs 2.92 Crores, or 6.30% of FY24 revenue. The disclosure does not establish that this price or order value belongs to the 800.62 million-unit L1 tender, so this should not be treated as the tender’s confirmed value.

The company’s historical average realization for government institutional sales is not reported, nor is the tender’s quoted unit price disclosed in the cited L1 announcement. Therefore, a reliable price comparison cannot be made; the Rs 0.37 per-unit figure is only an implied reference from the separate CMSS order, not a validated historical benchmark.

Latest disclosed installed capacity is approximately 806 million condoms annually, or 80.6 crore units, across 15 production lines. This is up from approximately 562 million units previously reported. ^[4]

Capacity requirement

Assuming the order is 8 crore units, or 80 million condoms, it represents approximately 9.93% of the reported annual installed capacity:

• Order: 80 million units
• Installed capacity: 806 million units
• Derived requirement: 80 ÷ 806 = 9.93%

On capacity arithmetic alone, the order appears executable within the existing plant; there is no disclosed order-specific requirement for additional capital expenditure. The company has separately reported total capex of approximately Rs 62 Crores, with Rs 24 Crores already spent on a 307-million-unit capacity expansion, but that investment was described as part of broader capacity enhancement rather than being linked specifically to this order. ^[4]

What remains uncertain

The evidence does not disclose:

• Current capacity-utilization levels;
• The volume reserved for existing commercial or private-label customers;
• The order’s delivery schedule or production phasing;
• Whether the order requires dedicated tooling, packaging, certification, or working-capital investment.

Therefore, the correct conclusion is: the 8-crore order does not appear to require incremental manufacturing capex based on disclosed capacity, but the company may need to allocate roughly 10% of annual capacity to it. Whether that allocation displaces existing commercial/private-label production cannot be determined without utilization and contract-level volume disclosures.

One important distinction: if the reference is instead to the 800.62-million-unit CMSS L1 tender, that is approximately 80.06 crore units, not 8 crore. It would be nearly equivalent to the reported annual capacity, but it was described as an L1 bid rather than a finalized contract, and the filing did not disclose contract value, award timing, or supply schedule. ^[1]

The CMSS L1 tender cannot be assigned a tender-level EBITDA margin from the disclosed information. The filing identifies Anondita Medicare as the L1 bidder for 800.62 million units, but does not disclose the contract value, award timing, supply schedule, or cost structure. ^[5]

Margin comparison

The latest annual KPI series reports the following company-wide EBITDA margins:

• FY24: 19.84%
• FY25: 30.15%
• FY26: 36.77% ^[2]

These are blended annual company margins, whereas the CMSS tender would be a fixed-price institutional contract. The filing specifically warns that latex-cost increases may not be recoverable under government tender pricing, creating downside risk to tender margins. ^[2]

Accordingly, the tender economics may be less margin-flexible than the FY26 company-wide 36.77% EBITDA margin, but it is not possible to determine whether the tender is above or below that margin without the awarded price and tender-specific manufacturing, packaging, logistics and other costs. The L1 status should also not be treated as a secured order until award and commercial terms are disclosed. ^[5]

Payment cycle

A typical government-institutional payment cycle—such as 60, 90 or 120 days—is not stated in the cited receivables or working-capital disclosures. It would therefore be inappropriate to infer one from the tender’s execution timetable.

For comparison, a separate CMSS order disclosed in June 2026 required 50% of the quantity to be supplied within 60 days and the balance between 61 and 120 days; those are delivery milestones, not payment terms. ^[3]

Implication: the key diligence gaps are the tender price, cost-per-unit and payment terms. Until these are disclosed, the tender can support volume visibility but not a reliable margin or working-capital assessment.